Literature DB >> 19823068

Role of metabolic syndrome components in HIV-associated sensory neuropathy.

Beau M Ances1, Florin Vaida, Debralee Rosario, Jennifer Marquie-Beck, Ronald J Ellis, David M Simpson, David B Clifford, Justin C McArthur, Igor Grant, J Allen McCutchan.   

Abstract

OBJECTIVES: Sensory neuropathy is a common peripheral nerve complication of HIV infection and highly active antiretroviral therapy. Metabolic syndrome (MetS), a cluster of risk factors for atherosclerosis and microvascular disease, is associated with sensory neuropathy in HIV-uninfected (HIV-negative) persons. We examined whether MetS or its components predispose individuals to HIV-associated sensory neuropathy (HIV-SN).
DESIGN: From a prospective multicenter cohort of 1556 HIV-positive patients, a subgroup (n = 130) with fasting laboratory tests and sensory neuropathy assessment was selected.
METHODS: Sensory neuropathy was defined by symmetrically decreased reflexes or sensation loss in the legs. MetS was defined by presence of at least three risk factors: mean arterial pressure of at least 100 mmHg; triglycerides (TRGs) of at least 150 mg/dl and high-density lipoprotein cholesterol of less than 40 mg/dl for male patients, less than 50 mg/dl for female patients; body mass index of more than 25 kg/m; plasma glucose (GLU) of at least 100 mg/dl and self-reported diabetes mellitus type 2. Multivariate logistic regression examined the association between HIV-SN and MetS.
RESULTS: After controlling for HIV-SN risk factors such as age, CD4 current, length of HIV infection, use of dideoxynucleoside reverse transcriptase inhibitors and protease inhibitors, MetS was not associated with HIV-SN (P = 0.72). However, when each MetS component was assessed, elevated TRG was a significant risk factor for HIV-SN. From the larger cohort, both diabetes mellitus type 2 (odds ratio = 1.4, P < 0.01) and elevated TRG (odds ratio = 1.4, P = 0.01) were risk factors for HIV-SN.
CONCLUSION: The risk of HIV-SN was increased for diabetes mellitus type 2 and elevated TRG but not for other MetS components. Both increase the risk of sensory neuropathy in HIV-populations, but the mechanism(s) remains unclear.

Entities:  

Mesh:

Year:  2009        PMID: 19823068      PMCID: PMC2896813          DOI: 10.1097/QAD.0b013e328332204e

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  23 in total

Review 1.  HIV-associated distal symmetrical polyneuropathy: clinical features and nursing management.

Authors:  B Swanson; J M Zeller; J A Paice
Journal:  J Assoc Nurses AIDS Care       Date:  1998 Mar-Apr       Impact factor: 1.354

2.  The metabolic syndrome influences the risk of chronic complications in patients with type II diabetes.

Authors:  B Isomaa; M Henricsson; P Almgren; T Tuomi; M R Taskinen; L Groop
Journal:  Diabetologia       Date:  2001-09       Impact factor: 10.122

3.  Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study.

Authors:  A Carr; K Samaras; A Thorisdottir; G R Kaufmann; D J Chisholm; D A Cooper
Journal:  Lancet       Date:  1999-06-19       Impact factor: 79.321

Review 4.  Recent developments in the HIV neuropathies.

Authors:  Carlos A Luciano; Carlos A Pardo; Justin C McArthur
Journal:  Curr Opin Neurol       Date:  2003-06       Impact factor: 5.710

5.  Aggregation of features of the metabolic syndrome is associated with increased prevalence of chronic complications in Type 2 diabetes.

Authors:  L A Costa; L H Canani; H R K Lisbôa; G S Tres; J L Gross
Journal:  Diabet Med       Date:  2004-03       Impact factor: 4.359

6.  Temporal trends in the incidence of HIV-1-related neurologic diseases: Multicenter AIDS Cohort Study, 1985-1992.

Authors:  H Bacellar; A Muñoz; E N Miller; B A Cohen; D Besley; O A Selnes; J T Becker; J C McArthur
Journal:  Neurology       Date:  1994-10       Impact factor: 9.910

7.  HIV-associated distal sensory polyneuropathy in the era of highly active antiretroviral therapy: the Manhattan HIV Brain Bank.

Authors:  Susan Morgello; Lydia Estanislao; David Simpson; Anthony Geraci; Alessandro DiRocco; Pieter Gerits; Elizabeth Ryan; Tatiana Yakoushina; Shafat Khan; Rashid Mahboob; Mubasher Naseer; David Dorfman; Victoria Sharp
Journal:  Arch Neurol       Date:  2004-04

8.  Peripheral nerve function in HIV infection: clinical, electrophysiologic, and laboratory findings.

Authors:  M Tagliati; J Grinnell; J Godbold; D M Simpson
Journal:  Arch Neurol       Date:  1999-01

9.  Incidence of and risk factors for HIV-associated distal sensory polyneuropathy.

Authors:  G Schifitto; M P McDermott; J C McArthur; K Marder; N Sacktor; L Epstein; K Kieburtz
Journal:  Neurology       Date:  2002-06-25       Impact factor: 9.910

Review 10.  Metabolic disorders and cardiovascular risk in HIV-infected patients treated with antiretroviral agents.

Authors:  Massimo Fantoni; Cosmo Del Borgo; Camillo Autore; Giuseppe Barbaro
Journal:  Ital Heart J       Date:  2002-05
View more
  11 in total

Review 1.  HIV-associated sensory neuropathy: risk factors and genetics.

Authors:  Peter R Kamerman; Antonia L Wadley; Catherine L Cherry
Journal:  Curr Pain Headache Rep       Date:  2012-06

2.  Pontocerebellar contribution to postural instability and psychomotor slowing in HIV infection without dementia.

Authors:  Edith V Sullivan; Margaret J Rosenbloom; Torsten Rohlfing; Carol A Kemper; Stanley Deresinski; Adolf Pfefferbaum
Journal:  Brain Imaging Behav       Date:  2011-03       Impact factor: 3.978

Review 3.  An Overview of Human Immunodeficiency Virus Type 1-Associated Common Neurological Complications: Does Aging Pose a Challenge?

Authors:  Anantha Ram Nookala; Joy Mitra; Nitish S Chaudhari; Muralidhar L Hegde; Anil Kumar
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

4.  A survey of the management, control, and complications of diabetes mellitus in patients attending a diabetes clinic in Blantyre, Malawi, an area of high HIV prevalence.

Authors:  Danielle B Cohen; Theresa J Allain; Simon Glover; Daniel Chimbayo; Helen Dzamalala; Helma W C Hofland; Ndaziona P K Banda; Eduard E Zijlstra
Journal:  Am J Trop Med Hyg       Date:  2010-09       Impact factor: 2.345

5.  The relationship between race and HIV-distal sensory polyneuropathy in a large cohort of US women.

Authors:  Yaacov Anziska; Elizabeth P Helzner; Howard Crystal; Marshall J Glesby; Michael Plankey; Kathleen Weber; Elizabeth Golub; Pamela Burian
Journal:  J Neurol Sci       Date:  2011-11-27       Impact factor: 3.181

6.  Insulin resistance and cognition among HIV-infected and HIV-uninfected adult women: the Women's Interagency HIV Study.

Authors:  Victor Valcour; Pauline Maki; Peter Bacchetti; Kathryn Anastos; Howard Crystal; Mary Young; Wendy J Mack; Mardge Cohen; Elizabeth T Golub; Phyllis C Tien
Journal:  AIDS Res Hum Retroviruses       Date:  2011-10-18       Impact factor: 2.205

7.  Hypertriglyceridemia in combination antiretroviral-treated HIV-positive individuals: potential impact on HIV sensory polyneuropathy.

Authors:  Sugato Banerjee; J Allen McCutchan; Beau M Ances; Reena Deutsch; Patricia K Riggs; Lauren Way; Ronald J Ellis
Journal:  AIDS       Date:  2011-01-14       Impact factor: 4.177

8.  Sensory neuropathy and metabolic risk factors in human immune deficiency virus infected South Africans receiving protease inhibitors.

Authors:  John-Randel Vermaak; Joel A Dave; Naomi Levitt; Jeannine M Heckmann
Journal:  AIDS Res Ther       Date:  2015-09-23       Impact factor: 2.250

9.  Prevalence of peripheral neuropathy and its associated demographic and health status characteristics, among people on antiretroviral therapy in Rwanda.

Authors:  David Kabagema Tumusiime; Francois Venter; Eustasius Musenge; Aimee Stewart
Journal:  BMC Public Health       Date:  2014-12-19       Impact factor: 3.295

10.  Peripheral neuropathy in patients with human immunodeficiency viral infection at a tertiary hospital in Ghana.

Authors:  Peter Puplampu; Vincent Ganu; Ernest Kenu; William Kudzi; Patrick Adjei; Leticia Grize; Michael Käser
Journal:  J Neurovirol       Date:  2019-04-26       Impact factor: 2.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.